Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

Inclusion Criteria: * Males and females aged at least 40 years or older. * Onset of symptoms of an acute attack of primary angle-closure in the study eye within the 120 hours prior to the planned study drug administration. * Best-corrected visual acuity (BCVA) 20/40 or better in the study eye after resolution of the acute attack. * Received successful treatment for the acute attack of angle-closure, and have undergone laser iridotomy with intraocular pressure in the study eye \<25mm Hg. * Sufficiently clear ocular media and adequate pupil dilation to allow the optic nerve and fovea to be visualized and assessed in the study eye. * Female subjects must be: (1) post menopausal, (2) surgically sterile, or (3) using an effective means of contraception. Exclusion Criteria: * Previously diagnosed with glaucoma in either eye. * The time planned for study drug administration is more than 120 hours from the onset of the symptoms. * History of chronic angle-closure in either eye. * Secondary angle-closure/secondary angle-closure glaucoma in the study eye. * Monocular subjects. * Prior incisional intraocular surgery. * Inability to perform a reliable visual field test on Day 0 in the study eye. * History of panretinal photocoagulation or macular laser photocoagulation in the study eye. * History of active malignancy within the last 5 years (however, non facial, basal cell carcinoma is allowed). * History of myocardial infarction within the last 6 months. * Received any drugs known to…